David W. Butterly, MD

Related Content

Services

• Kidney Care
• Transplants

Department / Division:
Medicine / Nephrology

Address:
DUMC 3014
Durham, NC 27710

Appointment Telephone:
919-668-7630

Office Telephone:
919-660-6865

Fax Telephone:
919-668-3994

• MD, Duke University School of Medicine, 1987

• Internal Medicine, Duke University Medical Center, 1987-1990
• Nephrology, Duke University Medical Center, 1990-1992

Clinical Interests:
Transplantation, consultative nephrology

Research Interests:
As a Clinician and Clinical Researcher in the Division of Nephrology my practice is mainly focussed on patients with end stage renal disease.  I am co-Director of a maintenance hemodialysis unit which cares for approximately 110 patients on maintenance hemodialysis.  In addition, I see patients three days weekly through the Private Diagnostic Clinic.  We see a variety of consultative nephrology problems, but our major focus remains Aend stage renal disease and renal transplantation@.  In the Renal Transplant Clinic, we see patients both pre- and post-transplant.  Over the last two years we have transplanted 90-100 patients annually  and care for several hundred other patients who are on the active transplant list.

My research interests thus relate primarily to end stage renal disease.  In the dialysis unit we are currently involved in a multi-center NIH-sponsored trial called the AHEMO Trial@, which is looking at causes of long-term morbidity and mortality in the dialysis population and the effect on the dialysis prescription.  In addition, our group has been active in maintenance of long-term hemodialysis access in the prospective of monitoring of vascular access to extend long-term graft survival.  In the transplantation arena, we will soon be stating another multi-center trial to evaluate a new anti-lymphocyte antibody for the treatment of acute cellular rejection.  This will be a multi-center randomized trial evaluating this new antibody versus OKT-3, which is currently standard of care.  We are also interested in bone disease after transplantation and the prevention of acute rejection with other pharmacologic mechanisms and are establishing trials and interventions to evaluate these.

KEY WORDS:
End stage renal disease, vascular access, renal transplantation, post-transplantation osseous disorders, consultative Nephrology.

Representative Publications:
5. Butterly DW, Spurney RF, Ruiz P, Griffiths R, Albrightson C, and Coffman TC. A role for leukotrienes in cyclosporine nephrotoxicity. Kid Int, Vol 2, 2586-2593, 2000. (2000)

4. Butterly DW and Schwab SJ. Renal Artery Stenosis: The Case for Conservative Management. Editorial. Mayo Clin Proc, Vol 75, No 5, (May) 435-437, 2000. (2000)

3. Howell DN, Smith SR, Butterly DW, Klassen PS, Krigman HR, Burchette JL, Miller SE. Diagnosis and Management of BK Polyomavirus Infections in Renal Transplant Recipients. Transplantation, Vol 68, No 9, (November) 1279-1288, 1999. (1999)

2. Kovalik ED, Raymond JF, Albers FJ, Berkoben MS, Butterly DW, Montella B, Conlon PJ. A clustering of epidural abscesses in chronic hemodialysis patients. Risks of salvaging infected access catheters. JASN 7:2264-2267, 1996. (1996)

1. Smith SR, Minda SA, Samsa GP, Harrell FE Jr., Gunnells JC, Coffman TM, Butterly DW. Late withdrawal of cyclosporine in stable renal transplant recipients. Am J Kid Dis 26(3): 487-494. 1995. (1995)